Stoke Therapeutics Prepares for Phase 3 Study of Zorevunersen for Dravet Syndrome
Stoke Therapeutics, Inc. (NASDAQ: STOK) recently announced plans to launch a Phase 3 study of zorevunersen, aiming to develop the first disease-modifying treatment for Dravet syndrome. The company disclosed this information in a Form 8-K filing with the Securities and Exchange Commission. The Phase 3 study, named EMPEROR, will assess zorevunersen’s efficacy in reducing major […]
More Stories
Apple (NASDAQ:AAPL) Shares Down 2.7% – What’s Next?
Apple Inc. (NASDAQ:AAPL – Get Free Report) shares traded down 2.7% on Friday . The company traded as low as...
SoFi Technologies (NASDAQ:SOFI) Shares Down 3.1% – What’s Next?
SoFi Technologies, Inc. (NASDAQ:SOFI – Get Free Report) shares dropped 3.1% during mid-day trading on Friday . The company traded...
Palo Alto Networks (NASDAQ:PANW) Trading Down 0.4% – Here’s What Happened
Palo Alto Networks, Inc. (NASDAQ:PANW – Get Free Report)’s share price was down 0.4% on Friday . The company traded...
CCM Investment Advisers LLC Sells 11,369 Shares of Phillips 66 (NYSE:PSX)
CCM Investment Advisers LLC lessened its position in Phillips 66 (NYSE:PSX – Free Report) by 10.8% during the 4th quarter,...
Hilltop National Bank Trims Stock Holdings in Booking Holdings Inc. (NASDAQ:BKNG)
Hilltop National Bank lowered its position in shares of Booking Holdings Inc. (NASDAQ:BKNG – Free Report) by 5.0% in the...
Hilltop National Bank Increases Stock Position in Vanguard FTSE Emerging Markets ETF (NYSEARCA:VWO)
Hilltop National Bank grew its stake in Vanguard FTSE Emerging Markets ETF (NYSEARCA:VWO – Free Report) by 11.3% during the...